초록 ▼

A process of nutripriming plant somatic embryos prior to sowing, comprising contacting an imbibed plant somatic embryo with a solution containing one or more dissolved nutrients, preferably including sucrose as one of the nutrients. The invention includes germinated embryos produced by the process,

A process of nutripriming plant somatic embryos prior to sowing, comprising contacting an imbibed plant somatic embryo with a solution containing one or more dissolved nutrients, preferably including sucrose as one of the nutrients. The invention includes germinated embryos produced by the process, and a method of producing seedlings or full-grown plants incorporating the nutripriming step. The method preferably makes use of a growth medium containing the nutrient or nutrients used in the nutripriming step.

대표청구항 ▼

A process of nutripriming plant somatic embryos prior to sowing, comprising contacting an imbibed plant somatic embryo with a solution containing one or more dissolved nutrients, preferably including sucrose as one of the nutrients. The invention includes germinated embryos produced by the process,

A process of nutripriming plant somatic embryos prior to sowing, comprising contacting an imbibed plant somatic embryo with a solution containing one or more dissolved nutrients, preferably including sucrose as one of the nutrients. The invention includes germinated embryos produced by the process, and a method of producing seedlings or full-grown plants incorporating the nutripriming step. The method preferably makes use of a growth medium containing the nutrient or nutrients used in the nutripriming step. tical excipients, the excipients including a bulking agent and one or more protectants, wherein the excipients are included in amounts effective to provide an adenovirus composition having an infectivity of at least 60% of the starting infectivity when stored for one month at -20° centigrade. 2. The adenovirus composition of claim 1, further defined as having an infectivity of at least 60% of the starting infectivity when stored for six months at 4° centigrade. 3. The adenovirus composition of claim 1, further defined as a freeze dried composition. 4. The composition of claim 3, wherein the freeze dried composition was prepared from an aqueous composition comprising a non-reducing sugar in a concentration of from about 2% to 10% (w/v). 5. The composition of claim 4, wherein the freeze dried composition was prepared from an aqueous composition comprising a non-reducing sugar in a concentration of from about 4% to 8%. 6. The composition of claim 5, wherein the freeze dried composition was prepared from an aqueous composition comprising a non-reducing sugar in a concentration of from about 5% to 6%. 7. The composition of claim 3, wherein the freeze dried composition was prepared from an aqueous composition comprising a lyoprotectant in a concentration of from about 0.5% to 5% (w/v). 8. The composition of claim 7, wherein the freeze dried composition was prepared from an aqueous composition comprising a lyoprotectant in a concentration of from about 1% to 4%. 9. The composition of claim 8, wherein the freeze dried composition was prepared from an aqueous composition comprising a lyoprotectant in a concentration of from about 1% to 3%. 10. The composition of claim 3, wherein the bulking agent is further defined as a bulking agent which forms crystals during freezing. 11. The composition of claim 3, wherein the freeze dried composition was prepared from an aqueous composition comprising a bulking agent in a concentration of from about 1% to 10% (w/v). 12. The composition of claim 11, wherein the freeze dried composition was prepared from an aqueous composition comprising a bulking agent in a concentration of from about 3% to 8%. 13. The composition of claim 12, wherein the freeze dried composition was prepared from an aqueous composition comprising a bulking agent in a concentration of from about 5% to 7%. 14. The composition of claim 1, wherein the bulking agent is mannitol, inositol, lactitol, xylitol, isomaltol, sorbitol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silcate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose or methylcellulose. 15. The composition of claim 14, wherein said bulking agent is mannitol. 16. The composition of claim 15, further defined as an aqueous composition comprising the bulking agent in a concentration of from about 1% to about 10% (w/v). 17. The composition of claim 16, wherein the aqueous composition comprises the bulking agent in a concentration of from about 3% to 8%. 18. The composition of claim 17, wherein the aqueous composition comprises the bulking agent in a concentration of from about 5% to 7%. 19. The composition of claim 1, wherein said protectant is further defined as including a cryoprotectant. 20. The composition of claim 19, wherein said cryoprotectant is a non-reducing sugar. 21. The composition of claim 20, wherein the non-reducing sugar is sucrose or trehalose. 22. The composition of claim 21, wherein said cryoprotectant is sucrose. 23. The composition of claim 20, further defined as an aqueous composition comprising the non-reducing sugar in a concentration of from about 2% to about 10% (w/v). 24. The composition of claim 23, wherein the aqueous composition comprises the sugar in a concentration of from about 4% to 8%. 25. The composition of claim 24, wherein the aqueous composition comprises the sugar in a concentration of from about 5% to 6%. 26. The composition of claim 19, wherein the cryoprotectan t is niacinamide, creatinine, monosodium glutamate, dimethyl sulfoxide or sweet whey solids. 27. The composition of claim 1, wherein said protectant includes a lyoprotectant. 28. The composition of claim 27, wherein said lyoprotectant is human serum albumin, bovine serum albumin, PEG, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 or Tween-80. 29. The composition of claim 28, wherein said lyoprotectant is human serum albumin. 30. The composition of claim 18, further defined as an aqueous composition comprising the lyoprotectant in a concentration of from about 0.5% to about 5% (w/v). 31. The composition of claim 30, wherein the aqueous composition comprises the lyoprotectant in a concentration of from about 1% to about 4%. 32. The composition of claim 31, wherein the aqueous composition comprises the lyoprotectant in a concentration of from about 1% to about 3%. 33. The composition of claim 27, further defined as comprising both a lyoprotectant and a cryoprotectant. 34. The adenovirus composition of claim 1, further defined as having an infectivity of at least 60% of the starting infectivity when stored for three months at -20° centigrade. 35. The adenovirus composition of claim 1, further defined as having an infectivity of at least 60% of the starting infectivity when stored for six months at -20° centigrade. 36. The adenovirus composition of claim 1, further defined as having an infectivity of at least 60% of the starting infectivity when stored for one month at 4° centigrade. 37. The adenovirus composition of claim 1, further defined as having an infectivity of at least 60% of the starting infectivity when stored for three months at 4° centigrade. 38. A method for preparation of a long-term, storage stable adenovirus formulation, comprising the steps of: (a) providing adenovirus and combining said adenovirus with a solution comprising a buffer, a bulking agent, a cryoprotectant and a lyoprotectant; and (b) lyophilizing said solution, whereby lyophilization of said solution produces a freeze-dried cake of said adenovirus formulation having an infectivity of at least 60% of the starting infectivity when stored for one month at -20° centigrade. 39. The method of claim 38, wherein said bulking agent is mannitol, inositol, lactitol, xylitol, isomaltol, sorbitol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silcate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose or methylcellulose. 40. The method of claim 39, wherein said bulking agent is mannitol. 41. The method of claim 40, wherein mannitol comprises about 0.5% to about 8% (w/v) of said formulation. 42. The method of claim 38, wherein said cryoprotectant is sucrose, dextrose, lactose, trehalose, glucose, maltose, niacinamide, creatinine, monosodium glutamate dimethyl sulfoxide or sweet whey solids. 43. The method of claim 42, wherein said cryoprotectant is sucrose. 44. The method of claim 38, wherein said sucrose comprises about 2.5% to about 10% (w/v) of said formulation. 45. The method of claim 38, wherein said lyoprotectant is human serum albumin, bovine serum albumin, PEG, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 or Tween-80. 46. The method of claim 45, wherein said lyoprotectant is human serum albumin. 47. The method of claim 38, wherein said buffer is Tris-HCl, TES, HEPES, mono-Tris, brucine tetrahydrate, EPPS, tricine, or histidine. 48. The method of claim 47, wherein said buffer is present in said formulation at a concentration at about 1 mM to 50 mM. 49. The method of claim 48, wherein said buffer is Tris-HCl. 50. The method of claim 49, wherein said Tris-HCl is included in a concentration of from a